對照品 > 標準品 > 歐洲藥典標準品 >
產(chǎn)品基本信息
產(chǎn)品編號：S870000
產(chǎn)品名稱：Suvorexant
產(chǎn)品CAS：1030377-33-3
規(guī)格含量：50mg
產(chǎn)品價格：面議
聯(lián)系我們:
產(chǎn)品詳細介紹
標準品編號:
S870000
名稱:
Suvorexant
別名:
[(7R)-4-(5-Chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]-methanone; 5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole; MK 4305; [(R)-4-(5-Chloro-benzooxazol-2-yl)-7-methyl-[1,4]diazepan-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone
CAS號:
1030377-33-3
分子式:
C??H??ClN?O?
外觀:
白色至Pale Beige Solid
熔點:
131-133°C
分子量:
450.92
儲存:
Room Temperature
溶解度:
Chloroform (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated)
類別:
Research Tools; Pharmaceutical/API Drug Impurities/Metabolites;
應用:
Suvorexant (MK-4305) is a dual (non-selective) orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It works by turning off wakefulness rather than by inducing sleep. Users of higher doses had an increased rate of suicidal ideation.
參考文獻
Cox, C., et al.: J. Med. Chem., 53, 5320 (2010); Baxter, C., et al.: Org. Process Res. Dev., 15, 367 (2011); Winrow, C., et al.: J. Neurogenet., 25, 52 (2011); Mieda, M., et al.: CNS Drugs, 27, 83 (2013); Osborne, R.: Nat. Rev. Drug Discov., 12, 492 (2013)
?您的位置：
